Applied Genetic Technologies - AGTC Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGTC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGTC, but not buy additional shares or sell existing shares.
View AGTC analyst ratings or view top-rated stocks.

8 brokerages have issued 12 month price objectives for Applied Genetic Technologies' shares. Their AGTC share price forecasts range from $3.00 to $16.00. On average, they expect the company's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 1,855.6% from the stock's current price.
View analysts price targets for AGTC or view top-rated stocks among Wall Street analysts.

Applied Genetic Technologies' stock was trading at $1.90 at the beginning of 2022. Since then, AGTC stock has decreased by 80.3% and is now trading at $0.3750.
View the best growth stocks for 2022 here.

Applied Genetic Technologies saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,380,000 shares, a drop of 34.3% from the October 31st total of 2,100,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is presently 1.2 days.
View Applied Genetic Technologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our AGTC earnings forecast.

Applied Genetic Technologies Co. (NASDAQ:AGTC) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same quarter in the previous year, the business earned ($0.60) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Applied Genetic Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.18%), Renaissance Technologies LLC (1.68%), Colony Group LLC (0.65%), Citadel Advisors LLC (0.63%), Virtu Financial LLC (0.17%) and Price T Rowe Associates Inc. MD (0.16%). Insiders that own company stock include Gerald Anthony Reynolds, Patrick Johan Hendrik Krol, Stephen W Potter and Susan B Washer.
View institutional ownership trends.

Shares of AGTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGTC stock can currently be purchased for approximately $0.38.

Applied Genetic Technologies (NASDAQ:AGTC) has a market capitalization of $25.36 million and generates $320,000.00 in revenue each year. The biotechnology company earns $-68,940,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The official website for the company is www.agtc.com. The biotechnology company can be reached via phone at (386) 462-2204 or via email at david.carey@finnpartners.com.